WO2000061175A3 - Use of pegylated interferon alpha in melanoma therapy - Google Patents
Use of pegylated interferon alpha in melanoma therapy Download PDFInfo
- Publication number
- WO2000061175A3 WO2000061175A3 PCT/US2000/009129 US0009129W WO0061175A3 WO 2000061175 A3 WO2000061175 A3 WO 2000061175A3 US 0009129 W US0009129 W US 0009129W WO 0061175 A3 WO0061175 A3 WO 0061175A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pegylated interferon
- interferon alpha
- melanoma therapy
- melanoma
- alfa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU42046/00A AU771569B2 (en) | 1999-04-08 | 2000-04-06 | Melanoma therapy |
BR0009646-6A BR0009646A (en) | 1999-04-08 | 2000-04-06 | Melanoma therapy |
HU0200775A HU230057B1 (en) | 1999-04-08 | 2000-04-06 | Melanoma therapy |
DK05002951T DK1535622T3 (en) | 1999-04-08 | 2000-04-06 | Melanoma therapy |
NO20014852A NO328111B1 (en) | 1999-04-08 | 2001-10-05 | Use of a pegylated interferon alfa-2b for the manufacture of a medicament for the treatment of a patient having a surgically removed melanoma. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28836699A | 1999-04-08 | 1999-04-08 | |
US09/288,366 | 1999-04-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000061175A2 WO2000061175A2 (en) | 2000-10-19 |
WO2000061175A3 true WO2000061175A3 (en) | 2001-02-01 |
Family
ID=23106795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/009129 WO2000061175A2 (en) | 1999-04-08 | 2000-04-06 | Use of pegylated interferon alpha in melanoma therapy |
Country Status (22)
Country | Link |
---|---|
EP (3) | EP2025344B1 (en) |
JP (1) | JP2000319195A (en) |
CN (1) | CN1390132A (en) |
AR (1) | AR023398A1 (en) |
AT (3) | ATE296639T1 (en) |
AU (1) | AU771569B2 (en) |
BR (1) | BR0009646A (en) |
CA (1) | CA2303992A1 (en) |
CO (1) | CO5170404A1 (en) |
CY (1) | CY1108922T1 (en) |
DE (3) | DE60045591D1 (en) |
DK (2) | DK1043026T3 (en) |
ES (2) | ES2319776T3 (en) |
HK (2) | HK1032349A1 (en) |
HU (1) | HU230057B1 (en) |
MY (1) | MY126763A (en) |
NO (1) | NO328111B1 (en) |
PE (1) | PE20010027A1 (en) |
PT (2) | PT1043026E (en) |
TW (1) | TWI292320B (en) |
WO (1) | WO2000061175A2 (en) |
ZA (1) | ZA200108173B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103476943A (en) * | 2011-03-10 | 2013-12-25 | 普罗维克图斯药品公司 | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998048840A1 (en) * | 1997-04-29 | 1998-11-05 | Schering Corporation | Polyethylene glycol-interferon alpha conjugates for therapy of infection |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4492537A (en) | 1982-12-10 | 1985-01-08 | Awerkamp John B | Fluid-operated oil or water well pump |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
JP2514950B2 (en) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | Chemically modified protein, its production method and intermediate |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
EP0730470B1 (en) | 1993-11-10 | 2002-03-27 | Enzon, Inc. | Improved interferon polymer conjugates |
US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
JP2758154B2 (en) | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | Liquid preparations containing interferon |
TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
-
2000
- 2000-04-06 HU HU0200775A patent/HU230057B1/en not_active IP Right Cessation
- 2000-04-06 AR ARP000101574A patent/AR023398A1/en unknown
- 2000-04-06 JP JP2000105524A patent/JP2000319195A/en not_active Withdrawn
- 2000-04-06 AT AT00107101T patent/ATE296639T1/en active
- 2000-04-06 AT AT05002951T patent/ATE419001T1/en active
- 2000-04-06 CA CA002303992A patent/CA2303992A1/en not_active Abandoned
- 2000-04-06 CN CN00808452A patent/CN1390132A/en active Pending
- 2000-04-06 BR BR0009646-6A patent/BR0009646A/en not_active Application Discontinuation
- 2000-04-06 EP EP08020311A patent/EP2025344B1/en not_active Expired - Lifetime
- 2000-04-06 PE PE2000000310A patent/PE20010027A1/en not_active Application Discontinuation
- 2000-04-06 EP EP05002951A patent/EP1535622B1/en not_active Expired - Lifetime
- 2000-04-06 PT PT00107101T patent/PT1043026E/en unknown
- 2000-04-06 PT PT05002951T patent/PT1535622E/en unknown
- 2000-04-06 ES ES05002951T patent/ES2319776T3/en not_active Expired - Lifetime
- 2000-04-06 DK DK00107101T patent/DK1043026T3/en active
- 2000-04-06 WO PCT/US2000/009129 patent/WO2000061175A2/en active Application Filing
- 2000-04-06 CO CO00025236A patent/CO5170404A1/en not_active Application Discontinuation
- 2000-04-06 DE DE60045591T patent/DE60045591D1/en not_active Expired - Lifetime
- 2000-04-06 AT AT08020311T patent/ATE496631T1/en not_active IP Right Cessation
- 2000-04-06 EP EP00107101A patent/EP1043026B1/en not_active Expired - Lifetime
- 2000-04-06 AU AU42046/00A patent/AU771569B2/en not_active Ceased
- 2000-04-06 DE DE60041290T patent/DE60041290D1/en not_active Expired - Lifetime
- 2000-04-06 DK DK05002951T patent/DK1535622T3/en active
- 2000-04-06 DE DE60020444T patent/DE60020444T2/en not_active Expired - Lifetime
- 2000-04-06 TW TW089106309A patent/TWI292320B/en not_active IP Right Cessation
- 2000-04-06 ES ES00107101T patent/ES2239954T3/en not_active Expired - Lifetime
- 2000-04-07 MY MYPI20001454A patent/MY126763A/en unknown
-
2001
- 2001-03-26 HK HK01102202A patent/HK1032349A1/en not_active IP Right Cessation
- 2001-10-04 ZA ZA200108173A patent/ZA200108173B/en unknown
- 2001-10-05 NO NO20014852A patent/NO328111B1/en not_active IP Right Cessation
-
2005
- 2005-11-02 HK HK05109748.1A patent/HK1075416A1/en not_active IP Right Cessation
-
2009
- 2009-03-24 CY CY20091100351T patent/CY1108922T1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998048840A1 (en) * | 1997-04-29 | 1998-11-05 | Schering Corporation | Polyethylene glycol-interferon alpha conjugates for therapy of infection |
Non-Patent Citations (4)
Title |
---|
BUKOWSKI RONAL ET AL: "Phase I Study of Polyethylene Glycol ( PEG ) Interferon Alpha -2B ( PEG INTRON ) in Patients with Solid Tumors (Meeting abstract).", PROC ANNU MEET AM SOC CLIN ONCOL, vol. 18, May 1999 (1999-05-01), pages A1719, XP000953163 * |
KIRKWOOD JOHN M ET AL: "Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The eastern cooperative oncology group trial EST 1684.", JOURNAL OF CLINICAL ONCOLOGY, vol. 14, no. 1, 1996, pages 7 - 17, XP000953174, ISSN: 0732-183X * |
TALPAZ M ET AL: "Phase I study of pegylated-interferon alpha-2a (PEGASYSTM) in patients with chronic myelogenous leukemia (CML).", BLOOD, vol. 94, no. 10 SUPPL. 1 PART 1, 15 November 1999 (1999-11-15), pages 530a, XP000953172, ISSN: 0006-4971 * |
TALPAZ M ET AL: "Phase I study of polyethylene glycol (PEG) interferon alpha-2B (Intron-A) in CML patients.", BLOOD, vol. 92, no. 10 SUPPL. 1 PART 1-2, 15 November 1998 (1998-11-15), pages 251A, XP000953118, ISSN: 0006-4971 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GEP20094798B (en) | (s,s)-reboxetine for treating chronic pain | |
AU2002341558A1 (en) | Compositions and methods useful for non-invasive delivery of therapeutic molecules to the bloodstream | |
DK1827500T3 (en) | Pegylated liposomal doxorubicin in combination with ecteinescidin 743 | |
MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
AU9018898A (en) | Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments | |
WO1999004772A3 (en) | Use of levobupivacaine | |
AU3247593A (en) | Therapeutic combinations useful in the treatment of gastroesophageal reflux disease | |
EP1440690A3 (en) | Treatment of neurotic disorders | |
PL342099A1 (en) | Therapeutic agents | |
HUP0003546A3 (en) | Compositions for administering taxanes orally to human patients | |
WO2001045715A3 (en) | Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain | |
EP1304108A3 (en) | Anti-arrhythmic composition and methods of treatment | |
SE9902597D0 (en) | New use | |
AU2162202A (en) | Antitumor therapy comprising distamycin derivatives | |
ZA967915B (en) | Therapeutic administration of hemoglobin in cardiac arrest | |
WO2000061174A3 (en) | Use of pegylated interferon alpha for renal cell carcinoma treatment | |
WO2000061175A3 (en) | Use of pegylated interferon alpha in melanoma therapy | |
IL131478A0 (en) | Methods for treatment of scar tissue | |
WO2000078800A3 (en) | Combined decorin binding protein and outer surface protein compositions and methods of use | |
AU2003255843A1 (en) | 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain | |
WO2000051631A3 (en) | Pegylated alpha interferon for hiv therapy | |
WO2003072019A3 (en) | Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog | |
WO2004073627A3 (en) | Novel therapeutic method and compositions for topical administration | |
EP1221945A4 (en) | Methods, pharmaceutical and therapeutic compositions for administering adenosine | |
WO1998036778A8 (en) | Sustained drug delivery and compositions useful therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00808452.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 514416 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/08173 Country of ref document: ZA Ref document number: 200108173 Country of ref document: ZA |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |